FATE

$0.00

(

0.00%

)
Quote details

stock

Fate Therapeutics Inc

NASDAQ | FATE

1.07

USD

0.00

(

0.00%

)

AT CLOSE (AS OF Aug 14, 2025)

$130M

MARKET CAP

-

P/E Ratio

-1.49

EPS

$4.2

52 Week High

$0.66

52 Week Low

LIFE SCIENCES

Sector

FATE Chart

Recent Chart
Price Action
1D
Candles

Trade Smarter

Automate your trading workflow with powerful tools — built for serious traders.

Icon For Time-schedule

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Icon For Search

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Icon For Clipboard-list

Journal

Record your trades and performance to improve your trading with AfterPullback's Trading Journal

FATE Technicals

Tags:

FATE Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $14M
Total Revenue $14M
Cost Of Revenue $19M
Costof Goods And Services Sold $19M
Operating Income -$210M
Selling General And Administrative $74M
Research And Development $135M
Operating Expenses $224M
Investment Income Net -
Net Interest Income $17M
Interest Income $17M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $19M
Income Before Tax -$186M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$186M
Comprehensive Income Net Of Tax -
Ebit -$196M
Ebitda -$177M
Net Income -$186M

Revenue & Profitability

Earnings Performance

FATE Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $441M
Total Current Assets $292M
Cash And Cash Equivalents At Carrying Value $36M
Cash And Short Term Investments $36M
Inventory -
Current Net Receivables $3.5M
Total Non Current Assets $149M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $28M
Short Term Investments $243M
Other Current Assets $9.3M
Other Non Current Assets -
Total Liabilities $122M
Total Current Liabilities $39M
Current Accounts Payable $9.4M
Deferred Revenue -
Current Debt -
Short Term Debt $15M
Total Non Current Liabilities $83M
Capital Lease Obligations $85M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $85M
Other Current Liabilities $14M
Other Non Current Liabilities $5.1M
Total Shareholder Equity $319M
Treasury Stock -
Retained Earnings -$1.4B
Common Stock $114K
Common Stock Shares Outstanding $114M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$123M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $19M
Capital Expenditures $730K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $12M
Cashflow From Financing $100M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$186M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $14M
Total Revenue $14M
Cost Of Revenue $19M
Costof Goods And Services Sold $19M
Operating Income -$210M
Selling General And Administrative $74M
Research And Development $135M
Operating Expenses $224M
Investment Income Net -
Net Interest Income $17M
Interest Income $17M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $19M
Income Before Tax -$186M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$186M
Comprehensive Income Net Of Tax -
Ebit -$196M
Ebitda -$177M
Net Income -$186M

FATE News

FATE Profile

Fate Therapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.

Discover more tools and features to empower your trading
Explore Features

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.